ClinicalTrials.gg
Active, not recruitingNCT06373367PrEPSUpdated Oct 9, 2025

Preeclampsia Educational Program Study (PrEPS)

An interventional study of Illustration based application and Text based application in Preeclampsia, Preeclampsia Severe and Preeclampsia Mild, sponsored by MemorialCare Health System. Active, not recruiting at 1 site in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-10-09.

Sponsored by MemorialCare Health System · Not applicable, Interventional, and Other

Phase
Not applicable
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Study summary

Preeclampsia complicates approximately 8% of all pregnancies. A critical factor of outpatient monitoring is patient education; specifically, education regarding nature of the disease, ongoing short- and long-term risks, and warning signs and symptoms for worsening of disease. This study aims to compare patient knowledge using a novel illustration based app compared to standard discharge instructions.

Read the detailed description

Preeclampsia complicates approximately 8% of all pregnancies. While many patients improve following delivery, the disease process remains a leading cause for postpartum morbidity and mortality. A critical factor of outpatient monitoring is patient education; specifically, education regarding nature of the disease, ongoing short- and long-term risks, and warning signs and symptoms for worsening of disease. There is a gap in the literature regarding effective, patient-centered educational tools specifically addressing these elements, especially in the postpartum period.

The investigators propose a pilot, randomized controlled trial of postpartum patients with preeclampsia. The intervention of interest is an illustration-based, educational mobile device application (app) focused on the short- and long-term risks associated with preeclampsia and warning signs and symptoms of worsening disease postpartum. The control for this study will be the same information in a text-only format, also accessed through a mobile device app.

The investigators central hypothesis is that an illustration-based app will improve knowledge of preeclampsia among postpartum patients compared to text-only educational material.

Specific Aim 1: Compare the difference in preeclampsia knowledge score from text-only versus illustration-based education 24 hours post intervention (short-term). The investigators hypothesize that patients who receive illustration-based education will have a) higher preeclampsia knowledge scores at 24 hours post-intervention compared to text-only educational materials and b) a greater increase in preeclampsia knowledge score from baseline (pre-test) compared to text-only education.

Specific Aim 2: Compare the difference in preeclampsia knowledge score from text-only versus illustration-based education >4 weeks post intervention (long-term). The investigators hypothesize that patients who receive illustration-based education will have a) higher preeclampsia knowledge scores at > 4 weeks post-intervention compared to text-only educational materials and b) a greater increase in preeclampsia knowledge score from baseline (pre-test) compared to text-only education.

02

Conditions studied

  • Preeclampsia
  • Preeclampsia Severe
  • Preeclampsia Mild
  • Preeclampsia Postpartum

Browse trials for

Keywords

  • preeclampsia
  • education
03

In context

Pre-Eclampsia

916 studies on the registry are indexed under Pre-Eclampsia; 243 are open to participants now.

This study's enrollment of 36 is below the median of 110 across 480 interventional studies indexed under Pre-Eclampsia.

Browse Pre-Eclampsia studies →

Lead sponsor

MemorialCare Health System is the lead sponsor of 21 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Preeclampsia with or without severe features
  • Able to read and speak English
  • Consistent access to mobile device with QR-reading capability and ability to access mobile-device application.
  • Pre-and postnatal care provided by OB Clinic (resident clinic) or Magella (maternal-fetal medicine)

Exclusion criteria

Exclusion Criteria:

  • Patient age \< 18 years old
  • Non-English speaking
  • Current enrollment in another trial targeting postpartum preeclampsia parameters
  • Arm width >40cm (XL Cuff)
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    Illustration

    This study arm will receive education via an illustration based application

    Other: Illustration based application

  • Active comparator
    Text

    This study arm will receive education via text based application

    Other: Text based application

Interventions

  • OtherIllustration based application

    Illustrations regarding the cause, risks, and warning signs of preeclampsia

  • OtherText based application

    Standard preeclampsia discharge instructions

06

What researchers measure

Primary outcomes

  1. Preeclampsia knowledge score - short

    Short term preeclampsia knowledge score. Scored from 0-24, with 24 demonstrating the most correct answers to the assessment

    Time frame: Measured at 24 hours postpartum

Secondary outcomes

  1. Preeclampsia knowledge score - long

    Long term preeclampsia knowledge score. Scored from 0-24, with 24 demonstrating the most correct answers to the assessment

    Time frame: Measured between 4 - 6 weeks postpartum

  2. GAD-7 score

    Generalized anxiety score. A score of 0-4 demonstrating none or minimal anxiety, 5-9 mild anxiety, 10-14 moderate anxiety, 15-21 severe anxiety

    Time frame: Measured between 4-6 weeks postpartum

  3. 72 hour BP check

    Adherence to a blood pressure check

    Time frame: Measured 72 hours after hospital discharge

  4. Number of participants who attend a postpartum visit

    Adherence to one postpartum visit

    Time frame: Measured within 6 weeks postpartum

  5. Daily BP recordings

    Percent of daily blood pressure recordings at home

    Time frame: Measured within 6 weeks postpartum

  6. Accessed material

    Number of times information accessed postpartum

    Time frame: Measured at 6 weeks postpartum

  7. Unplanned readmission

    Number of unplanned readmissions related to preeclampsia

    Time frame: Measured at 6 weeks postpartum

07

Study locations

1 site
08

References and documents

Publications

  • Bruno AM, Allshouse AA, Metz TD, Theilen LH. Trends in Hypertensive Disorders of Pregnancy in the United States From 1989 to 2020. Obstet Gynecol. 2022 Jul 1;140(1):83-86. doi: 10.1097/AOG.0000000000004824. Epub 2022 Jun 7. PubMed 35849460 ↗
  • Dol J, Hughes B, Bonet M, Dorey R, Dorling J, Grant A, Langlois EV, Monaghan J, Ollivier R, Parker R, Roos N, Scott H, Shin HD, Curran J. Timing of maternal mortality and severe morbidity during the postpartum period: a systematic review. JBI Evid Synth. 2022 Sep 1;20(9):2119-2194. doi: 10.11124/JBIES-20-00578. PubMed 35916004 ↗
  • Shree R, Hatfield-Timajchy K, Brewer A, Tsigas E, Vidler M. Information needs and experiences from pregnancies complicated by hypertensive disorders: a qualitative analysis of narrative responses. BMC Pregnancy Childbirth. 2021 Nov 2;21(1):743. doi: 10.1186/s12884-021-04219-0. PubMed 34724906 ↗
  • You WB, Wolf MS, Bailey SC, Grobman WA. Improving patient understanding of preeclampsia: a randomized controlled trial. Am J Obstet Gynecol. 2012 May;206(5):431.e1-5. doi: 10.1016/j.ajog.2012.03.006. Epub 2012 Mar 13. PubMed 22542120 ↗
  • You WB, Wolf M, Bailey SC, Pandit AU, Waite KR, Sobel RM, Grobman W. Factors associated with patient understanding of preeclampsia. Hypertens Pregnancy. 2012;31(3):341-9. doi: 10.3109/10641955.2010.507851. Epub 2010 Sep 22. PubMed 20860492 ↗
  • Chames MC, Livingston JC, Ivester TS, Barton JR, Sibai BM. Late postpartum eclampsia: a preventable disease? Am J Obstet Gynecol. 2002 Jun;186(6):1174-7. doi: 10.1067/mob.2002.123824. PubMed 12066093 ↗
  • Collier AY, Molina RL. Maternal Mortality in the United States: Updates on Trends, Causes, and Solutions. Neoreviews. 2019 Oct;20(10):e561-e574. doi: 10.1542/neo.20-10-e561. PubMed 31575778 ↗
  • Ditisheim A, Wuerzner G, Ponte B, Vial Y, Irion O, Burnier M, Boulvain M, Pechere-Bertschi A. Prevalence of Hypertensive Phenotypes After Preeclampsia: A Prospective Cohort Study. Hypertension. 2018 Jan;71(1):103-109. doi: 10.1161/HYPERTENSIONAHA.117.09799. Epub 2017 Nov 13. PubMed 29133363 ↗
  • Gestational Hypertension and Preeclampsia: ACOG Practice Bulletin, Number 222. Obstet Gynecol. 2020 Jun;135(6):e237-e260. doi: 10.1097/AOG.0000000000003891. PubMed 32443079 ↗

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 9, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06373367
Lead sponsor
MemorialCare Health System
Responsible party
Megan Oakes (MD MCSI, MemorialCare Health System) — Principal investigator
First posted
Apr 18, 2024
Start date
Oct 1, 2024
Primary completion
May 29, 2025
Completion
May 31, 2026 (estimated)
Last update
Oct 9, 2025

Study contacts

Megan Oakes, MD MSCI
principal investigator · Magella Medical Group, MemorialCare

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion